24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
Identifieur interne : 000266 ( PubMed/Corpus ); précédent : 000265; suivant : 00026724-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
Auteurs : Lucia Ricciardi ; Francesco Bove ; Kristy J. Espay ; Francesco Lena ; Nicola Modugno ; Yu-Yan Poon ; Robert Krikorian ; Alberto J. Espay ; Alfonso FasanoSource :
- Movement disorders : official journal of the Movement Disorder Society [ 1531-8257 ] ; 2016.
English descriptors
- KwdEn :
- Aged, Antiparkinson Agents (administration & dosage), Antiparkinson Agents (pharmacology), Carbidopa (administration & dosage), Carbidopa (pharmacology), Drug Combinations, Female, Follow-Up Studies, Gels, Humans, Infusions, Parenteral, Levodopa (administration & dosage), Levodopa (pharmacology), Male, Middle Aged, Muscle Rigidity (drug therapy), Muscle Rigidity (etiology), Outcome Assessment (Health Care), Parkinson Disease (complications), Parkinson Disease (drug therapy), Sleep Wake Disorders (drug therapy), Sleep Wake Disorders (etiology).
- MESH :
- chemical , administration & dosage : Antiparkinson Agents, Carbidopa, Levodopa.
- chemical , pharmacology : Antiparkinson Agents, Carbidopa, Levodopa.
- complications : Parkinson Disease.
- drug therapy : Muscle Rigidity, Parkinson Disease, Sleep Wake Disorders.
- etiology : Muscle Rigidity, Sleep Wake Disorders.
- Aged, Drug Combinations, Female, Follow-Up Studies, Gels, Humans, Infusions, Parenteral, Male, Middle Aged, Outcome Assessment (Health Care).
DOI: 10.1002/mds.26564
PubMed: 26946221
Links to Exploration step
pubmed:26946221Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.</title><author><name sortKey="Ricciardi, Lucia" sort="Ricciardi, Lucia" uniqKey="Ricciardi L" first="Lucia" last="Ricciardi">Lucia Ricciardi</name><affiliation><nlm:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bove, Francesco" sort="Bove, Francesco" uniqKey="Bove F" first="Francesco" last="Bove">Francesco Bove</name><affiliation><nlm:affiliation>Istituto di Neurologia, Universitá Cattolica del Sacro Cuore, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Espay, Kristy J" sort="Espay, Kristy J" uniqKey="Espay K" first="Kristy J" last="Espay">Kristy J. Espay</name><affiliation><nlm:affiliation>Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lena, Francesco" sort="Lena, Francesco" uniqKey="Lena F" first="Francesco" last="Lena">Francesco Lena</name><affiliation><nlm:affiliation>Neuromed Institute, Pozzilli, IS, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Modugno, Nicola" sort="Modugno, Nicola" uniqKey="Modugno N" first="Nicola" last="Modugno">Nicola Modugno</name><affiliation><nlm:affiliation>Neuromed Institute, Pozzilli, IS, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Poon, Yu Yan" sort="Poon, Yu Yan" uniqKey="Poon Y" first="Yu-Yan" last="Poon">Yu-Yan Poon</name><affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Krikorian, Robert" sort="Krikorian, Robert" uniqKey="Krikorian R" first="Robert" last="Krikorian">Robert Krikorian</name><affiliation><nlm:affiliation>Cognitive Aging Program, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Espay, Alberto J" sort="Espay, Alberto J" uniqKey="Espay A" first="Alberto J" last="Espay">Alberto J. Espay</name><affiliation><nlm:affiliation>Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Fasano, Alfonso" sort="Fasano, Alfonso" uniqKey="Fasano A" first="Alfonso" last="Fasano">Alfonso Fasano</name><affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2016">2016</date><idno type="RBID">pubmed:26946221</idno><idno type="pmid">26946221</idno><idno type="doi">10.1002/mds.26564</idno><idno type="wicri:Area/PubMed/Corpus">000266</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">000266</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.</title><author><name sortKey="Ricciardi, Lucia" sort="Ricciardi, Lucia" uniqKey="Ricciardi L" first="Lucia" last="Ricciardi">Lucia Ricciardi</name><affiliation><nlm:affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, London, UK.</nlm:affiliation></affiliation></author><author><name sortKey="Bove, Francesco" sort="Bove, Francesco" uniqKey="Bove F" first="Francesco" last="Bove">Francesco Bove</name><affiliation><nlm:affiliation>Istituto di Neurologia, Universitá Cattolica del Sacro Cuore, Rome, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Espay, Kristy J" sort="Espay, Kristy J" uniqKey="Espay K" first="Kristy J" last="Espay">Kristy J. Espay</name><affiliation><nlm:affiliation>Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Lena, Francesco" sort="Lena, Francesco" uniqKey="Lena F" first="Francesco" last="Lena">Francesco Lena</name><affiliation><nlm:affiliation>Neuromed Institute, Pozzilli, IS, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Modugno, Nicola" sort="Modugno, Nicola" uniqKey="Modugno N" first="Nicola" last="Modugno">Nicola Modugno</name><affiliation><nlm:affiliation>Neuromed Institute, Pozzilli, IS, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Poon, Yu Yan" sort="Poon, Yu Yan" uniqKey="Poon Y" first="Yu-Yan" last="Poon">Yu-Yan Poon</name><affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author><author><name sortKey="Krikorian, Robert" sort="Krikorian, Robert" uniqKey="Krikorian R" first="Robert" last="Krikorian">Robert Krikorian</name><affiliation><nlm:affiliation>Cognitive Aging Program, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Espay, Alberto J" sort="Espay, Alberto J" uniqKey="Espay A" first="Alberto J" last="Espay">Alberto J. Espay</name><affiliation><nlm:affiliation>Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.</nlm:affiliation></affiliation></author><author><name sortKey="Fasano, Alfonso" sort="Fasano, Alfonso" uniqKey="Fasano A" first="Alfonso" last="Fasano">Alfonso Fasano</name><affiliation><nlm:affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Movement disorders : official journal of the Movement Disorder Society</title><idno type="eISSN">1531-8257</idno><imprint><date when="2016" type="published">2016</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Aged</term><term>Antiparkinson Agents (administration & dosage)</term><term>Antiparkinson Agents (pharmacology)</term><term>Carbidopa (administration & dosage)</term><term>Carbidopa (pharmacology)</term><term>Drug Combinations</term><term>Female</term><term>Follow-Up Studies</term><term>Gels</term><term>Humans</term><term>Infusions, Parenteral</term><term>Levodopa (administration & dosage)</term><term>Levodopa (pharmacology)</term><term>Male</term><term>Middle Aged</term><term>Muscle Rigidity (drug therapy)</term><term>Muscle Rigidity (etiology)</term><term>Outcome Assessment (Health Care)</term><term>Parkinson Disease (complications)</term><term>Parkinson Disease (drug therapy)</term><term>Sleep Wake Disorders (drug therapy)</term><term>Sleep Wake Disorders (etiology)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiparkinson Agents</term><term>Carbidopa</term><term>Levodopa</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Parkinson Disease</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Muscle Rigidity</term><term>Parkinson Disease</term><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" qualifier="etiology" xml:lang="en"><term>Muscle Rigidity</term><term>Sleep Wake Disorders</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Aged</term><term>Drug Combinations</term><term>Female</term><term>Follow-Up Studies</term><term>Gels</term><term>Humans</term><term>Infusions, Parenteral</term><term>Male</term><term>Middle Aged</term><term>Outcome Assessment (Health Care)</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">26946221</PMID><DateCreated><Year>2016</Year><Month>04</Month><Day>15</Day></DateCreated><DateCompleted><Year>2017</Year><Month>01</Month><Day>17</Day></DateCompleted><DateRevised><Year>2017</Year><Month>01</Month><Day>17</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1531-8257</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>4</Issue><PubDate><Year>2016</Year><Month>Apr</Month></PubDate></JournalIssue><Title>Movement disorders : official journal of the Movement Disorder Society</Title><ISOAbbreviation>Mov. Disord.</ISOAbbreviation></Journal><ArticleTitle>24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.</ArticleTitle><Pagination><MedlinePgn>597-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/mds.26564</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ricciardi</LastName><ForeName>Lucia</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Sobell Department of Motor Neuroscience and Movement Disorders, Institute of Neurology, University College London, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bove</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Istituto di Neurologia, Universitá Cattolica del Sacro Cuore, Rome, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espay</LastName><ForeName>Kristy J</ForeName><Initials>KJ</Initials><AffiliationInfo><Affiliation>Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lena</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Neuromed Institute, Pozzilli, IS, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Modugno</LastName><ForeName>Nicola</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Neuromed Institute, Pozzilli, IS, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Poon</LastName><ForeName>Yu-Yan</ForeName><Initials>YY</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Krikorian</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Cognitive Aging Program, Department of Psychiatry & Behavioral Neuroscience, University of Cincinnati, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Espay</LastName><ForeName>Alberto J</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fasano</LastName><ForeName>Alfonso</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J. Safra Program in Parkinson's Disease, Toronto Western Hospital, UHN, Division of Neurology, University of Toronto, Toronto, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2016</Year><Month>03</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Mov Disord</MedlineTA><NlmUniqueID>8610688</NlmUniqueID><ISSNLinking>0885-3185</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000978">Antiparkinson Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004338">Drug Combinations</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005782">Gels</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C009265">carbidopa, levodopa drug combination</NameOfSubstance></Chemical><Chemical><RegistryNumber>46627O600J</RegistryNumber><NameOfSubstance UI="D007980">Levodopa</NameOfSubstance></Chemical><Chemical><RegistryNumber>MNX7R8C5VO</RegistryNumber><NameOfSubstance UI="D002230">Carbidopa</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000978" MajorTopicYN="N">Antiparkinson Agents</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D002230" MajorTopicYN="N">Carbidopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004338" MajorTopicYN="N">Drug Combinations</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005782" MajorTopicYN="N">Gels</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007263" MajorTopicYN="N">Infusions, Parenteral</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007980" MajorTopicYN="N">Levodopa</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName><QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009127" MajorTopicYN="N">Muscle Rigidity</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="Y">Outcome Assessment (Health Care)</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010300" MajorTopicYN="N">Parkinson Disease</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012893" MajorTopicYN="N">Sleep Wake Disorders</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Parkinson's disease</Keyword><Keyword MajorTopicYN="N">intrajejunal levodopa</Keyword><Keyword MajorTopicYN="N">nonmotor symptoms</Keyword><Keyword MajorTopicYN="N">sleep</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2015</Year><Month>08</Month><Day>09</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2015</Year><Month>12</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2015</Year><Month>12</Month><Day>16</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2016</Year><Month>3</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2016</Year><Month>3</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2017</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">26946221</ArticleId><ArticleId IdType="doi">10.1002/mds.26564</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Canada/explor/ParkinsonCanadaV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000266 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 000266 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Canada
|area= ParkinsonCanadaV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:26946221
|texte= 24-Hour infusion of levodopa/carbidopa intestinal gel for nocturnal akinesia in advanced Parkinson's disease.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:26946221" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a ParkinsonCanadaV1
| This area was generated with Dilib version V0.6.29. |  |